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Abstract
Prion diseases, also known as transmissible spongiform encephalopathies, are a group of fatal neurodegenerative diseases
that include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in
humans. The ‘protein only hypothesis’ advocates that PrPSc, an abnormal isoform of the cellular protein PrPC, is the main
and possibly sole component of prion infectious agents. Currently, no effective therapy exists for these diseases at the
symptomatic phase for either humans or animals, though a number of compounds have demonstrated the ability to
eliminate PrPSc in cell culture models. Of particular interest are synthetic polymers known as dendrimers which possess the
unique ability to eliminate PrPSc in both an intracellular and in vitro setting. The efficacy and mode of action of the novel
anti-prion dendrimer mPPIg5 was investigated through the creation of a number of innovative bio-assays based upon the
scrapie cell assay. These assays were used to demonstrate that mPPIg5 is a highly effective anti-prion drug which acts, at
least in part, through the inhibition of PrPC to PrPSc conversion. Understanding how a drug works is a vital component in
maximising its performance. By establishing the efficacy and method of action of mPPIg5, this study will help determine
which drugs are most likely to enhance this effect and also aid the design of dendrimers with anti-prion capabilities for the
future.
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Introduction
Prion diseases are a group of fatal neurodegenerative diseases
that can be genetic, infectious or sporadic in origin. They include
scrapie in sheep, bovine spongiform encephalopathy (BSE) in
cattle, and Creutzfeldt-Jakob disease (CJD) in humans. The
‘protein only hypothesis’ advocates that PrPSc, a misfolded form of
the endogenous prion protein, is the main and possibly sole
component of prion infectious agents [1,2]. No effective therapy
exists for prion diseases at the symptomatic phase for either
humans or animals. However, several molecules including congo
red [3], sulphated polyanions [4], cyclic tetrapyrroles (porphyrins
and phthalocyanines) [5], branched polyamines [6,7], suramin [8],
STI571 [9] and quinacrine [10] have demonstrated the ability to
eliminate PrPSc in cell culture models. Synthetic macromolecules
known as dendrimers are a particularly interesting class of anti-
prion compounds as numerous dendrimer species possess the
ability to eliminate PrPSc in both an intracellular and in vitro
setting. Evidence suggests that this is achieved by interacting
directly with PrPSc and rendering it sensitive to proteases [6,7].
Within the cell this is thought to occur within acidic endosomes or
lysosomes [6] though recently it has been speculated that certain
dendrimers may eliminate PrPSc by inhibiting the conversion of
PrPC to PrPSc [11,12].
In the present work, we examined the anti-prion efficacy of
maltose modified poly(propylene imine) generation five dendri-
mers (mPPIg5) (Figure 1) and investigated their mode of action.
This new class of branched-polyamines differs from dendrimers
previously reported to possess anti-prion activity as they possess
neutral rather than cationic surface groups due to the presence of
maltose in their outer shell [13]. They exhibit a markedly reduced
toxicity over the more established cationic dendrimers yet still
retain their anti-prion activity [14].
The efficacy of an anti-prion drug in a cell culture system is
generally assessed by monitoring the elimination of protease
resistant PrPSc over time through the use of PK digestion (to
remove PrPC) and immunoblotting (to detect the remaining
protease resistant PrPSc). As western blotting is quite cumbersome
to perform and, at best, a semi-quantitative technique, we saw the
potential to develop the highly quantitative and high throughput
scrapie cell assay as a method of measuring the efficacy of anti-
prion drugs. The standard scrapie cell assay (sSCA) is an ELISA
spot assay and an alternative to the animal bioassay for the
detection of prions [15]. In the sSCA, susceptible cells are exposed
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for 4 days to a sample which potentially harbours infectious
prions. If prions are within this sample they will infect the cells and
propagate over time to detectable levels. The cells are then
attached to a Multiscreen 96 well plate and undergo numerous
treatments including a protease digestion step in which PrPC is
removed and an immuno-detection step where protease resistant
PrPSc is detected [15]. Infected cells are visualised as spots on the
Multiscreen plate membrane using a microscope and camera
system for quantification. We used the ELISA spot portion of this
system in reverse to monitor the decrease in PrPSc producing cells
over time following the application of mPPIg5. To achieve this,
the protease digestion step of the sSCA was altered to produce an
assay more suitable for detecting the decrease in prion infected
cells following treatment with a therapeutic agent. The modified
assay, called the modified SCA (mSCA), detects all forms of
protease resistant PrPSc (Table 1).
To determine how mPPIg5 was eliminating PrPSc from cells, we
exploited the unique intracellular processing of the PrPSc protein.
In prion infected cells, PrPC encounters PrPSc at an unidentified
region sometime after reaching the plasma membrane and is
converted to the misfolded isoform. About 1 hour after this event
residues 23–88 at the N-terminus of PrPSc are removed by a
proteolytic process that is believed to occur in an acidic endosome
or lysosome [16–18]. The truncated PrPSc formed by this event is
known as PrP27–30. PrP27–30 accumulates in lysosomes and has a
half-life of $24 hours [9,17]. For the sake of clarity, in this study
non-truncated protease resistant PrPSc will be referred to as Full
Length PrPSc (FL PrPSc) and truncated protease resistant PrPSc
will be referred to as PrP27–30.
In summary: PrPC RFL PrPScRPrP27–30.
As FL PrPSc is short lived, its intracellular level is closely related
to its production rate. If the synthesis of FL PrPSc is interfered
with, the level of detectable FL PrPSc drops rapidly. Thus the level
of FL PrPSc can be seen as a marker of the conversion of PrPC to
misfolded forms. There are two basic mechanisms by which a drug
can eliminate prions from a cell: (A) by increasing the degradation
of pre-existing PrPSc or (B) by inhibiting the production of prions
by blocking the conversion of PrPC to FL PrPSc. If a drug inhibits
the conversion of PrPC to FL PrPSc, a rapid drop in FL PrPSc
should occur. Thus, by monitoring the level of FL PrPSc we hoped
to gain an insight into the mechanism by which mPPIg5 cleared
PrPSc from cells.
A variation of the SCA, called the N terminal specific scrapie
cell assay (nSCA), was created to quantify FL PrPSc. This assay
was based on an assay previously developed by our laboratory to
detect PrPSc in its nascent state [19]. The nSCA specifically detects
FL PrPSc. It does not detect the truncated form (PrP27–30) which
represents the majority of PrPSc in the cell [20]. The nSCA uses
the protease trypsin to enable the detection of FL-PrPSc. Trypsin
digests all PrPC and cleaves protease resistant PrPSc at positions 23,
24, 37 and 48. Although these are N-terminal cleavage sites, the
majority of the N terminal including the Ocatpeptide Repeat
Figure 1. Schematic description of dendrimers PPIg4, PPIg5 and mPPIg5 used in this study. A) mPPIg5 is obtained by reductive
amination of PPIg5 [13,14]. B) Molecular structure of cationic 4th generation poly(propylene imine) (PPIg4) with the smallest size used in biological
experiments. C) Molecular weights for the dendrimers utilised in this study.
doi:10.1371/journal.pone.0055282.g001
mPPIg5 Inhibits PrPC Conversion to PrPSc
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e55282
region (OR) is left intact [21]. An antibody (SAF32) directed
against an epitope in the OR of the N-terminal can be used to
detect FL PrPSc [19]. This epitope is not present on PrP27–30 as the
N terminal region is cleaved in the formation of PrP27–30 [16,18].
Therefore, the use of an N terminal antibody to differentiate
between FL PrPSc and PrP27–30, and trypsin to remove PrPC but
leave the majority of the N terminal of FL PrPSc intact, enables the
nSCA to directly identify FL PrPSc present in a cell (Table 1). The
sSCA is not capable of this as the PK used in this assay cleaves the
N terminus of FL PrPSc reducing it to PrP27–30 (comparable to the
cleavage that occurs in lysosomes). Therefore in the sSCA, FL
PrPSc and PrP27–30 cannot be differentiated.
The ability to detect and quantify protease resistant PrPSc and
FL PrPSc provides a powerful approach in assessing the efficacy
and method of action of current and future therapeutics in the
treatment of prion diseases. In this study the mSCA and nSCA
were used to investigate the efficacy and mode of action of the
anti-prion therapeutic mPPIg5. The assays demonstrated that
mPPIg5 is a highly effective anti-prion drug which acts, at least in
part, through the inhibition of PrPC to PrPSc conversion in 22L
infected N2a cells.
Materials and Methods
Reagents and therapeutic compounds
All reagents used in this study were analytical grade, and unless
otherwise stated, obtained from Sigma. The poly(propylene imine)
generation four (PPIg4; DAB-Am32) and generation five (PPIg5;
DAB-Am64) dendrimers were obtained from SyMO-Chem
(Eindhoven, Netherland). PPIg5 dendrimers modified with a
dense maltose shell (mPPIg5; Mw 44,500 g/mol) were prepared
by a reductive amination of PPIg5 in the presence of maltose as
described previously [13,14]. Dendrimer stock compounds were
prepared as 20 mg/ml solutions in sterile H2O. Suramin was
prepared as a 200 mg/ml stock solution in 0.9% NaCl in dH2O.
STI571 (Stratech Scientific) was prepared as a 10 mM stock
solution in dimethyl sulfoxide. NH4Cl was prepared as a 1M stock
solution in Dulbecco’s Modified Eagle Medium (DMEM)(Gibco).
All stock solutions were sterilized by filtration through a 0.22 mm
syringe filter (Millipore).
Cell culture and treatment
N2a cells were kindly donated by Dr. Byron Caughey (Rocky
Mountain Laboratories, National Institutes of Health, Hamilton,
MT, USA) [22]. These were subcloned and infected with the
murine adapted scrapie prion strain RML by the method of
Bosque and Prusiner [23]. N2a#58 cells and N2a#58 cells
infected with the mouse adapted prion strain 22L (22LN2a#58),
were kindly donated by Dr Sylvain Lehmann (Institut de
Ge´ne´tique Humaine du CNRS, Montpellier, France). N2a#58
cells are N2a cells transfected with mouse PrPa/a and produce,6x
the normal levels of PrPC [24]. All cell lines were maintained as
monolayers at 37uC in 8% CO2 in cultivation media consisting of
Dulbecco’s Modified Eagle Medium (DMEM)(Gibco) supplement-
ed with 2 mM glutamine, 100U/ml penicillin, 100 mg/ml
streptomycin and 10% heat inactivated foetal bovine serum
(FBS)(Gibco). In addition, the transfected N2a#58 cells were
treated with 300 g/ml G418. The medium for all cell lines was
replaced every 2–3 days and cells typically reached confluence
after 4–5 days at which stage they were split for subculture. N2a
and ScN2a used for metabolic labelling were cultured as described
earlier [25]. For treatment of cells with various therapeutics, cells
were generally sub-passaged 24 hours prior to treatment at a
dilution that allowed cells to be confluent at the end of treatment.
Suramin, STI571, mPPIg5 and NH4Cl were diluted from stock
solutions in regular culture media to the stated concentrations.
Scrapie Cell Assay
The ELISA portion of the Scrapie cell assay (SCA) was adapted
from the protocol previously published by Klohn et al [15] and all
steps were carried out at room temperature unless otherwise
stated. The ELISPOT plate (MultiscreenHTS 96 well filtration
plates with Immobilon-P transfer membrane, 0.45 mm; Millipore)
was activated with 60 ml 70% methanol per well. The Methanol
was removed by vacuum (MultiScreen vacuum; Millipore), wells
washed twice with 160 ml PBS and 60 ml PBS added to each well
to prevent drying out. Cells to be examined were washed twice
with PBS and suspended in DMEM by gentle pipetting. Cells were
diluted to 100,000 or 25,000 cells per ml depending on experiment
and 200 ml of this dilution added to each well to give 20,000 or
5,000 cells per well. Cells were attached to the membrane by
vacuum and the elispot plate placed in an incubator at 60uC for
1 hour without its lid. After 1 hour, the plate was either wrapped
in cling film and stored at 4uC for up to two weeks or directly
treated with protease.
Protease treatment varied depending on the experiment. For the
standard scrapie cell assay 60 ml of PK (0.3 mg/ml for 5000 cells;
0.5 mg/ml for 20,000) diluted in lysis buffer (50 mM Tris HCl
pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.5% Triton
X-100) was used. For the modified and N terminal specific scrapie
cell assay, 60 ml of trypsin (10 mg/ml for 5000 cells; 15 mg/ml for
20,000 cells) diluted in PBS (pH7.4) was utilised. Protease
Table 1. Summary of the standard scrapie cell assay and variants developed in this study.
Assay Standard SCA Modified SCA N-terminal specific
(sSCA) (mSCA) SCA (nSCA)
Protease PK in lysis buffer Trypsin in PBS Trypsin in PBS
SAF83 SAF83 SAF32
Antibody
Recognises an epitope (aa 126–164) in
central region PrP
Recognises an epitope (aa 126–164) in
central region PrP
(Recognises an epitope (codon 58–89) in the
octarepeat region of the N terminal of PrP)
All protease resistant PrPSc All protease resistant PrPSc Protease resistant FL PrPSc only
PrP
isoform - PrP27–30 - PrP27–30
detected - FL PrPSc (converted to PrP27–30 by PK) - FL PrPSc
doi:10.1371/journal.pone.0055282.t001
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treatment was carried out at 37uC and 80rpm for one hour,
followed by one wash with 160 ml PBS. The reaction was stopped
by addition of 150 ml 2 mM PMSF (in PBS, pH 7.4) for
10 minutes. Cells were washed twice with 160 ml PBS, pH 7.4.
and denatured by treatment with 120 ml 3M guanidinium
thiocyanate (GSCN), 10mM Tris-HCl (pH 8) for 10 minutes.
Following this wells were washed four times with PBS, pH 7.4 and
incubated with 160 ml of Superblock (Pierce) for 1 hour. The
superblock was removed and 60 ml primary antibody in TBS-T/
1% non-fat milk powder (Marvel) added at the appropriate
dilution for 1 hour – For the sSCA and mSCA, SAF83 was used at
a final concentration of 20ng/ml. For the nSCA, SAF32 was
employed at a final concentration of 266ng/ml. The wells were
washed seven times with 160 ml TBS-T and incubated with 60ml
ALP-conjugated anti-mouse secondary antibody (0.1 mg/ml in
TBS-T/1% non-fat milk powder) for 1 hour. The wells were
washed eight times with TBS-T and signal developed by
incubation with 60 ml/well BCIP for 16 minutes in the dark.
The development was stopped by two washes with 160 ml dH2O.
The plastic casing at the back of the elispot plate was then
removed and the wells washed a further two times with 160 ml
dH2O. PrP
Sc positive cells were detected and quantified using the
Zeiss Elispot software system and Zeiss AX-10 imager (Zeiss).
Lysate preparation
For analysis of intracellular protein content, confluent cells were
washed twice with PBS, pH 7.4 and lysed with ice cold lysis buffer
(10 mM Tris, pH 7.4, 100 mM NaCl, 10 mM EDTA, 0.5%
deoxycholic acid, 0.5% Triton X-100) for 5 minutes. Cells were
detached from plate by pipetting and centrifuged at 1,0006g for
5 minutes to remove cellular debris. Protein concentration of the
lysate was measured by BCA assay (Pierce) according to the
manufacturer’s instructions. For lysis of cells in 4% sarkosyl in PBS
(pH 7.4), the same procedure as above was initially followed but
lysis was performed with 4% sarkosyl in PBS (pH 7.4), not cellular
lysis buffer. The lysate was subsequently homogenised by
successive passage through 20, and 23 gauge needles. Protein
concentration of the lysate was measured by BCA and the cell
lysates were stored at 220uC and thawed on ice before use. For
dendrimer treatment of lysates (lysate in 4% sarkosyl only) a final
concentration of 2.4 mg/ml mPPIg5 was incubated with samples
for 3 hours at 37uC and 450rpm. Protease resistant PrPSc content
of all lysates was analysed by proteinase K (PK) treatment for
30 minutes at 37uC at a ratio of 250:1 using an amount of 100 mg
cellular lysate (total protein) per sample. Reactions were stopped
by addition of 5 mM PMSF. The sample was centrifuged at
16,000 g for 30 minutes, supernatant discarded and pellet re-
suspended in 16 SDS sample buffer for immunoblot analysis.
Immunoblot Analysis
Protein samples in 16 SDS sample buffer were incubated for
5 minutes at 95uC prior to electrophoresis on a 12.5% SDS
polyacrylamide gel. After transfer (100 mV, 1 h) to a PVDF
membrane (Millipore) and rinsing in TBST (TBS-0.5% Tween
20), unspecific binding sites were blocked by incubation in 5%
dried milk powder (Marvel) in TBST for 1 h, with shaking (250
rpm). The membrane was washed five times in TBST (5 minutes
each, shaking at 250 rpm), and incubated with SAF83 (SPI Bio,
diluted to 20 ng/mL in TBST) overnight. The membrane was
washed 5 times and exposed to goat anti-mouse IgG-ALP
secondary antibody (Promega, diluted to 0.1 mg/ml in TBST)
for 1.5 hours, followed by five additional washing steps in TBST
(5 minutes each, shaking at 250 rpm). Blots were developed by
exposure to 10 mls 5-Bromo-4-chloro-3-indolyl phosphate (BCIP)
for 5 minutes, followed by two washes with dH2O. Developed
membranes were digitized (imaged) using the Fujifilm LAS 4000.
Purification of PrP27–30 from prion infected N2a cells
(ScN2a)
ScN2a cells were grown to confluence on 100 mm plates and
washed twice with 4mls PBS (pH 7.4). Cells were lysed with ice
cold 600 ml low detergent lysis buffer (10mM Tris, pH 7.4,
100 mM NaCl, 0.05% deoxycholic acid, 0.05% Triton X-100)
and centrifuged at 1,000 g for 5 mins to remove cellular debris.
Protein concentration of this postnuclear supernatant was
measured by BCA (Pierce). The lysate was treated with proteinase
K (PK) at a ratio of 1:50, protease to protein, for 2 hours at 37uC.
The reaction was stopped by the addition of 5 mM PMSF (1/20
dilution of 100 mM PMSF). 500 mg aliquots of the lysate were
transferred into 1.5 ml eppendorfs and centrifuged at 16,000g for
30 minutes. The supernatant was discarded and the pellet washed
twice in 100 ml PBS (pH 7.4) by centrifugation at 16,000 g for
4 minutes. The resulting pellet was re-suspended in 50 ml PBS
(pH 7.4) to give a final concentration of 10 mg/ml (before PK).
Inoculation of N2a cells with PrP27–30
N2a cells were seeded in a 96 well dish (for infection study) or 24
well dish (for nSCA validation) at a ratio of 20,000 and 150,000
cells per well respectively. Cells were incubated overnight in
regular culture media at 37uC, 8% CO2. PrP
27–30 purified from
ScN2a cells was diluted to various degrees in cultivation media and
added to the appropriate well. Cells were grown for 96 hours at
37uC and 8% CO2. The inoculated cells were either examined
after 1 hour (nSCA validation) or cultured for four days before
passaging at a 1/4 dilution, then cells cultured to confluence and
passaged a further 3 times at 1/10 dilution before analysis by
mSCA (Infection study).
Confocal Microscopy
Coverslips (13mm; Agar Scientific) were sterilised in 70% IMS
and incubated overnight in Poly-D-Lysine (50 mg/ml). Following a
rinse in sterile dH2O, coverslips were placed at the bottom of 6
well TC plates. N2a and N2a#58 cells were added at a dilution of
30,000 cells/well in cultivation media and let adhere to coverslips
for 24 hours. After 24 hours, media was removed and cultivation
media with either suramin (200 mg/ml) or mPPIg5 (20 mg/ml)
added. Mock treated cells were treated with cultivation media
+10 ml sterile dH2O. After 48 hours cells were fixed in 3%
Paraformaldehyde for 20 minutes, quenched with 30 mM Glycine
in PBS (pH 7.5) for 5 minutes and washed three times with PBS
(pH 7.4) in 6 well TC plates. Cells to be permeabilized were
treated with 0.1% Triton X-100 in PBS (pH 7.4) for 5 minutes
and washed three times with PBS (pH 7.4). Primary antibody was
applied for one hour (50 ml SAF32, 500 ng/ml in PBS). Coverslips
were washed three times with PBS and 50 ml Alexa-488
conjugated anti-mouse secondary antibody (5 mg/ml in PBS;
Invitrogen) applied. Following this, coverslips were washed once
with PBS, treated for 3mins with the nuclear stain Hoechst 33342
(1:5000 in PBS; Invitrogen), and washed twice with PBS.
Coverslips were mounted on glass slides using Mowiol and stored
in the dark for 24 hours. Immunostained cells on coverslips were
analysed by confocal microscopy using the Olympus FV1000
confocal microscope (Olympus). A 60x 1.35NA UPL SAPO
objective was used. All images were acquired equally; 2x zoom, a
scanning speed of 10.0 ms/pixel, with 3x kalman line averaging
and sequential acquisition.
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PIPLC analysis of cells
N2a#58 cells were seeded onto 60 mm plates and cultured for
24 hours. After 24 hours the media was removed, cells washed
once in PBS (pH 7.4) and treatment media added for 48 hours.
Treatment consisted of cultivation media with suramin (200 mg/
ml), mPPIg5 (20 mg/ml) or sterile dH2O (10 ml) for mock
treatment. After 48 hours media was removed and cells were
mock treated with serum free DMEM at 37uC or treated for
2 hours with 0.5U/ml PIPLC in serum free DMEM. The media
from all plates was collected and cells washed three times with PBS
(pH 7.4) before being lysed as described previously. The protein in
the media was ethanol precipitated and the PrPC content of this
and the lysed cells (25 mg) determined by immunoblotting.
Metabolic labelling
Metabolic labelling was carried out as described previously [26].
Briefly, N2a cells cultivated in 3.5 cm dishes were transfected with
1 mg DNA by a liposome-mediated method using LipofectAMINE
Plus reagent (Invitrogen) according to the manufacturer’s instruc-
tion. The mouse PrP construct used contain a 3F4 tag [25]. Cells
were starved for 30 minutes in methionine-free modified Eagles
medium (Invitrogen) and subsequently labelled for 1 hour with
300 mCi/ml L-[35S] methionine (Hartmann Analytics; .37 TBq/
mmol) in methionine-free modified Eagles medium (Invitrogen).
For the chase, the labelling medium was removed, and cells were
washed twice and incubated in complete medium for 4 hours.
When indicated, maltose modified Poly(propylene imine) gener-
ation 5 (mPPIg5) was present during the starving, labelling and
chase periods (final concentration 20 mg/ml). PrP was analysed by
immunoprecipitation with the monoclonal 3F4 antibody [25,27].




The modified scrapie cell assay (mSCA) was developed in this
study and is used to quantify the decrease in PrPSc producing cells
over time following treatment with a therapeutic. In comparison to
the standard scrapie cell assay (sSCA) which uses PK in lysis
buffer, the mSCA employs trypsin in PBS as the protease digestion
step necessary to remove PrPC. This produces more intense and
compact cells which are easier to quantify and results in an assay
better able to detect a decrease in PrPSc producing cells over time
(Figure S1). The mSCA was used to investigate the efficacy of
maltose modified PPI dendrimers (mPPIg5) in curing prion
infected cells. mPPIg5 has previously been shown to eliminate
PrPSc from RML infected N2a cells (ScN2a) [14]. To examine the
ability of mPPIg5 to cure cells infected with strains other than
RML, 22L infected N2a#58 cells (22LN2a#58) were treated with
20 mg/ml mPPIg5 for increasing periods of time and cells assessed
via the modified scrapie cell assay (mSCA) (Figure 2A). The mSCA
illustrates that mPPIg5 eliminates protease resistant PrPSc from
22LN2a#58 cells in a highly efficient manner and highlights the
promise of modified dendrimers as anti-prion therapeutics. The
traditional method of PrPSc detection – PK digestion and
immunoblot – was used to confirm the result (Figure 2B). The
optimum treatment concentration of mPPIg5 was also determined
using the mSCA (Figure S2) and found to be in agreement with
the literature at 10–20 mg/ml [14].
Intracellular method of action of mPPIg5
Dendrimers are believed to achieve their anti-prion effect by
acting directly on PrPSc within lysosomes and rendering them
sensitive to proteases [6]. The ability of dendrimers to render
PrPSc from brain homogenate protease sensitive in vitro supports
this [6,7]. mPPIg5 eliminated protease resistant PrPSc from 22L
infected N2a#58 cells (Figure 2), so it was expected that mPPIg5
would also be effective at eliminating protease resistant PrPSc from
lysates derived from 22L infected N2a#58 cells. However, whilst
mPPIg5 was able to eliminate protease resistant PrPSc from lysates
derived from RML infected cells in vitro, it had no effect on lysates
derived from 22L infected cells (Figure 3A). In contrast,
intracellular treatment with mPPIg5 eliminated protease resistant
PrPSc from both RML (Figure 3B) and 22L infected cells (Figure 2).
This suggested that the method by which mPPIg5 eliminated
PrPSc intracellularly and in vitro may be different – mPPIg5
dendrimers may not render PrPSc protease sensitive in vivo; the
presumed mode of action for dendrimers. They may interfere with
the PrPC R PrPSc conversion process. This possibility was
investigated by developing a variation of the SCA capable of
quantifying Full Length PrPSc (FL PrPSc) called the N terminal
specific SCA (nSCA).
The nSCA was created to directly quantify FL PrPSc. To
validate this assay and confirm that it only detects FL PrPSc and
not PrPC or PrP27–30, N2a cells were inoculated with exogenous
PrP27–30 for 1 hour and assayed by the mSCA and nSCA
(Figure 4A). (For details on production and validation of PrP27–30
see Fig S3). The nSCA did not detect PrP27–30. The mSCA (which
can detect PrP27–30) acted as a positive control to show that
Figure 2. mPPIg5 treatment of 22LN2a#58 cells. A) 22LN2a#58
cells were either treated with 20 mg/ml mPPIg5 or mock-treated for
increasing lengths of time before analysis of cells for PrPSc content via
mSCA. The % difference in PrPSc content between mPPIg5 and mock
treated cells at each time point was calculated and the decrease in PrPSc
over time plotted. Error bars represent SD; n = 3. B) 22LN2a#58 cells
were treated with 20 mg/ml mPPIg5 for increasing lengths of time
before detection of protease resistant PrPSc via PK digestion and
immunoblotting (lanes 3–10). Samples in lane 2 were not treated whilst
samples in lane 1 were not treated or PK digested. Apparent molecular
mass based on migration of protein standards is indicated for 17, 25,
and 30 kDa. n = 3.
doi:10.1371/journal.pone.0055282.g002
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PrP27–30 was associated with the cells and illustrated a dose
response curve matching the dilutions of inoculates used
(Figure 4A).
To demonstrate that the nSCA can detect FL PrPSc, RML
infected N2a cells (ScN2a) were inoculated with PrP27-30 and
nSCA and mSCA performed (Figure 4B). The nSCA detected the
endogenous FL PrPSc within the ScN2a cells but not the additional
exogenous PrP27–30. The mSCA detected both the endogenous FL
PrPSc and the exogenous and endogenous PrP27–30. These results
demonstrate the nSCA’s ability to differentiate between FL PrPSc
and PrP27–30 in prion infected cells. Having demonstrated that the
nSCA can selectively detect FL PrPSc, we sought to determine if
the nSCA could be used to deduce mPPIg59s intracellular mode of
action.
The hypothesis was:
1. If mPPIg5 interfered with the conversion of PrPC to FL PrPSc,
a rapid decrease in FL PrPSc levels would be expected; PrPC to
FL PrPSc conversion would be inhibited and so no new FL
PrPSc would be produced. Existing FL PrPSc is naturally
cleaved to PrP27–30 within ,1 hour of its synthesis [16,18] and
so FL PrPSc levels would be expected to drop rapidly.
2. If mPPIg5 acted in the lysosome to increase the degradation of
PrPSc, no short term effect would be observed on FL PrPSc;
mPPIg5 may induce some degradation of FL PrPSc, but PrPC
conversion to FL PrPSc would not be significantly perturbed
and so FL PrPSc levels would not be expected to drop rapidly
over the short term.
To validate this approach, two drugs with an established anti-
prion mode of action were also examined. Suramin is a drug
which achieves its anti-prion effect by inhibiting the conversion of
PrPC to PrPSc. It achieves this by inhibiting the regular trafficking
of PrPC and causing its aggregation as non-protease resistant
aggregates in a post ER/Golgi compartment. This alteration in
trafficking prevents its conversion to PrPSc [8]. STI571 is a
tyrosine kinase inhibitor whose effect on c-abl tyrosine kinase
results in the increased lysosomal degradation of PrPSc [9]. We
hypothesised that suramin would have a dramatic effect on FL
PrPSc levels over the first 48 hours of treatment whilst STI571
would have a minimal effect over this time period. The mode of
action of mPPIg5 could then be deduced by correlating its effect
on FL PrPSc with these drugs.
To investigate this, 22LN2a#58 cells were treated with suramin
(200 mg/ml), STI571 (10 mM) and mPPIg5 (20 mg/ml) for
increasing periods of time before analysis for FL PrPSc levels via
the nSCA and immunoblotting (Figure 5). Both suramin and
mPPIg5 treatment resulted in a rapid decrease of FL PrPSc levels
with ,80% of FL PrPSc eliminated after 12 hours. Contrary to
expectations, STI571 treatment also led to a rapid decrease in FL
PrPSc levels, though the decline in FL PrPSc levels was less
pronounced with ,50% eliminated after 12 hours. The rapid loss
in FL PrPSc levels upon STI571 treatment was unexpected. Pulse
chase experiments have demonstrated that STI571 does not
interfere with the production of protease resistant PrPSc [9].
Production of protease resistant PrPSc must involve the production
of FL PrPSc (PrPC R FL PrPSc R PrP27–30). Therefore the
decrease in FL PrPSc upon STI571 treatment while protease
resistant PrPSc production continued unabated was puzzling. One
explanation is that STI571 may increase the rate of truncation of
FL PrPSc. This would lead to a rapid decrease in detectable FL
PrPSc without affecting the production of protease resistant PrPSc.
STI571 inhibits the tyrosine kinase c-Abl, which is thought to
result in the increased lysosomal degradation of PrPSc [9]. Given
its effect on the lysosome, the ability of STI571 to increase the N
terminal truncation of FL PrPSc is therefore plausible. Although
not alluded to by the authors, this scenario is also supported by
examination of the original results from Ertmer et al (Figure 4A,
lane 1 vs 3; Ertmer et al., 2004).
The rapid loss of FL PrPSc observed in mPPIg5 treated cells
could be explained by an increased rate of FL PrPSc N terminal
truncation. NH4Cl was used to examine this possibility. NH4Cl
inhibits N terminal truncation of FL PrPSc by raising the pH of the
acidic endosome where this cleavage occurs. NH4Cl does not
interfere with the production of de novo PrPSc or the biogenesis and
trafficking of PrPC [16].
It was hypothesised:
1. If a compound inhibits the conversion of PrPC to FL PrPSc, no
difference between cells treated in the presence and absence of
NH4Cl should be observed; FL PrP
Sc is not being produced so
NH4Cl induced inhibition of truncation should have no effect.
2. If an anti-prion compound solely achieves its effect by
increasing the degradation of PrPSc isoforms (including FL
PrPSc), prion infected cells treated in the presence of NH4Cl
should produce a higher level of FL PrPSc than cells treated in
the absence of NH4Cl. There are at least two ways NH4Cl can
achieve this. a) NH4Cl may inhibit the anti-prion action of a
drug by raising the pH of the lysosome. In this instance, PrPSc
isoforms (including FL PrPSc) would not be degraded and so an
increase in the level of FL PrPSc would be observed in cells
treated in the presence of NH4Cl over cells treated in the
absence of NH4Cl. b) In the presence of NH4Cl, an anti-prion
Figure 3. mPPIg5 treatment of ScN2a cells and treatment of
lysates from RML and 22L infected N2a cells. A) RML infected N2a
cells and 22L infected N2a#58 cells were lysed in 4% sarkosyl (in PBS
pH 7.4). 100 mg of lysate was then left untreated or treated with
2.4 mg/ml of mPPIg5 dendrimers for 3 hours before analysis for
protease resistant PrPSc content by PK digestion and immunoblot. B)
RML infected N2a cells were treated with increasing concentrations of
mPPIg5 for 4 days before analysis by PK digest and immunoblot for
PrPSc. Apparent molecular mass based on migration of protein
standards is indicated for 17, 25, and 30 kDa in both panel A and B.
n = 3.
doi:10.1371/journal.pone.0055282.g003
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drug may still degrade PrPSc isoforms. However NH4Cl treated
cells will possess an increased level of FL PrPSc. Cells treated
with an anti-prion drug in the presence of NH4Cl will therefore
display a higher level of FL PrPSc than cells treated in the
absence of NH4Cl as there is more FL PrP
Sc to degrade.
To examine this hypothesis, 22LN2a#58 cells were treated for
48 hours with mPPIg5 (20 mg/ml), suramin (200 mg/ml) or
STI571 (10 mM) in the presence or absence of 2 mM NH4Cl
and analysed by nSCA (Figure 6). In the presence of NH4Cl,
22LN2a#58 control cells registered an increase in FL PrPSc over
non NH4Cl treated control cells (Figure 6). This confirms that
NH4Cl produces an increase in FL PrP
Sc by preventing its
truncation to PrP27–30.
Both mPPIg5 and suramin treatment of 22LN2a#58 cells
produced a decrease in FL PrPSc that was unaffected by NH4Cl
(Figure 6). This indicates that mPPIg5 is capable of inhibiting the
conversion of PrPC to FL PrPSc. Suramin served as a control in
this experiment for a drug known to inhibit the conversion of PrPC
to PrPSc [8].
STI571 was used as a control for a drug known to increase the
degradation of pre-existing PrPSc [9]. STI571 treatment of
22LN2a#58 cells resulted in a decrease of FL PrPSc that was
partially reversed by NH4Cl (Figure 6). NH4Cl inhibition of
STI5719s ability to clear PrPSc was previously reported and
attributed to NH4Cl raising the pH of the acidic lysosome where
STI571 induced degradation of PrPSc was thought to occur [9].
From this experiment we can conclude that mPPIg5 inhibits the
conversion of PrPC to FL PrPSc. It should be noted that these
results make no assumption about mPPIg59s ability to increase the
degradation of PrPSc, though it does rule this out as being
mPPIg’5s sole mechanism of action.
A possible explanation for mPPIg59s ability to inhibit the
conversion of PrPC to PrPSc is that mPPIg5 interferes with the
biogenesis or subcellular localization of the PrPC protein. mPPIg5
may prevent PrPC from localizing in lipid rafts at the plasma
membrane and thus prevent its conversion to PrPSc in a similar
manner to which suramin works for example [8]. To examine this
possibility, N2a#58 cells grown on coverslips were treated with
mPPIg5 or suramin and PrPC localization examined via confocal
microscopy (Figure 7A). Non-permeabilized cells were used to
specifically examine PrPC levels at the plasma membrane whilst
permeabilized cells were used to detect all PrPC within the cell.
The results illustrate that mPPIg5 treatment has no effect on the
localization of PrPC, which is still predominantly found at the
plasma membrane. In agreement with previous results, suramin
treatment of cells inhibited PrPC localization at the plasma
membrane and instead caused PrPC aggregation in what appears
to be a post-ER/Golgi compartment [8].
To confirm the confocal microscopy result, phosphatidylinosi-
tol-specific phospholipase C (PIPLC) was utilised. mPPIg5 and
mock treated N2a#58 cells were incubated with PIPLC, and
following this the cell media was collected and treated cells lysed.
The media was ethanol precipitated to obtain all protein. Both this
and the cellular lysate were then examined for PrPC content by
immunoblot (Figure 7B). The cellular lysate for both the control
and mPPIg5 treated cells exhibited a significant drop in PrPC
content following PIPLC treatment indicating PrPC was removed
from the plasma membrane. This PrPC was detectable in the
media, though at a lower level than expected. This discrepancy
can be explained by a diminished immunoblot signal from PrPC
cleaved by PIPLC [29]. There was no detectable difference
between the amount of PrPC released from the plasma membrane
in the control and mPPIg5 treated cells indicating that mPPIg5
had no effect on PrPC localization.
To ensure PrPC synthesis was not affected by mPPIg5
treatment, N2a cells were pulse radio labelled with [35S]
methionine in the presence or absence of mPPIg5 and the
synthesis of PrPC monitored (Figure 7C). mPPIg5 treated cells
Figure 4. Validation of nSCA. A) N2a cells and B) ScN2a cells were inoculated for 1.5 hours with increasing dilutions of PrP27–30. The infective
media was removed and replaced with regular DMEM for an additional 3 hours before cells were repeatedly washed with PBS and 20,000 cells
attached per well of an ELISPOT plate. Cells were examined via the nSCA and mSCA. Positive result is defined as .30 spots/20,000 cells. The software
used to count spots (infected cells) cannot count accurately above 1000 spots so a dose response curve is not observed with the mSCA for the ScN2a
cells inoculated with PrP27–30. Error bars represent SD; n = 2.
doi:10.1371/journal.pone.0055282.g004
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produced an equal amount of PrPC as the control cells indicating
mPPIg5 has no effect on PrPC synthesis.
Discussion
Maltose modified PPI (mPPI) dendrimers are a relatively new
class of anti-prion compounds with immense potential due to their
low cytotoxicity [14] and ability to cross the blood-to-brain barrier
[30]. In this study we developed and utilised novel forms of the
scrapie cell assay to demonstrate that the maltose modified PPI
dendrimer, mPPIg5, is a potent anti-prion drug which inhibits the
conversion of PrPC to PrPSc. In addition, we demonstrate that
mPPIg5 does not interfere with the biogenesis or processing of the
regular PrP isoform, indicating that modified dendrimers possess
significant potential as anti-prion therapeutics and as agents for
investigating the nature of prion diseases.
To deduce mPPIg59s intracellular mode of action, a novel assay
called the N terminal specific SCA (nSCA) was developed. The
nSCA was used to demonstrate that mPPIg5 inhibits the
conversion of PrPC to PrPSc (Figure 6). This is novel as previous
studies have suggested that dendrimers which eliminate PrPSc
from cells achieve their effect by enhancing the degradation of
PrPSc in acidic endosomes/lysosomes [6,7]. This working hypoth-
esis was based on three observations:
1. The alkalising lysomotrophic agent chloroquine, inhibited the
elimination of prions by dendrimers (PEI) [6].
2. Confocal microscopy showed dendrimers (PPI) localizing in
lysosomes [7].
3. The in vitro elimination of protease resistant PrPSc by
dendrimers (PEI and PPI) was greatest at an acidic pH [6,7].
Collectively, these findings argue that dendrimers with anti-
prion activity achieve their effect by increasing the degradation of
PrPSc. However when examined individually, each of the
arguments quickly becomes less robust. For example, chloroquine
has multiple effects on cells in addition to raising its lysosomal pH
such as altering protein trafficking and endocytosis [31,32]. In
addition, NH4Cl, another alkalising lysomotrophic agent, does not
inhibit the effect of PEI dendrimers [6] suggesting alkalisation of
acidic compartments alone is not sufficient. The finding that the in
vitro elimination of protease resistant PrPSc by dendrimers was
greatest at an acidic pH is also not conclusive as the in vitro anti-
prion action of dendrimers appears to involve the denaturation of
PrPSc and so an acidic pH enhancing this is not surprising. In
addition, an acidic pH is not necessary for the in vitro anti-prion
Figure 5. Effect of Suramin, STI571 and mPPIg5 treatment on
FL PrPSc levels. A) 22LN2a#58 cells were treated with either STI571
(10 mm), suramin (200 mg/ml), mPPIg5 (20 mg/ml) or mock treated for
increasing periods of time before analysis for FL PrPSc content by nSCA.
The % difference in PrPSc content between therapeutically treated and
mock treated cells at each time point was calculated for each drug
(STI571, Suramin and mPPIg5) and the decrease in FL PrPSc over time
plotted. Error bars represent SD; n = 3. B) To validate the result,
22LN2a#58 cells treated with STI571 (10 mm), suramin (200 mg/ml) and
mPPIg5 (20 mg/ml) for various periods of time were also lysed and
analysed for FL PrPSc content by trypsin digestion and immunoblotting
with SAF32 (Lanes 3–10). Samples in lane 2 were not treated whilst
samples in lane 1 were not treated or PK digested. Apparent molecular
mass based on migration of protein standards is indicated for 17, 25,
and 30 kDa. n = 3.
doi:10.1371/journal.pone.0055282.g005
Figure 6. Effect of NH4Cl on FL PrP
Sc levels. 22LN2a#58 cells were
mock treated or treated with mPPIg5 (20 mg/ml), STI571 (10 mM) or
suramin (200 mg/ml) in the presence or the absence of 2 mM NH4Cl for
48 hours before analysis for FL PrPSc content via nSCA. The number of
FL PrPSc containing cells in 20,000 mock treated control cells (- NH4Cl) is
taken as the 100% value on the Y axis. All subsequent results are
calculated from this. Results marked a, b, c and d are all statically
significantly different from one another (p,0.001); Analysed using a
Two-way ANOVA for PrPres, Dendrimer6NH4Cl (F4,88 = 7.99; P,0.001).
Post-hoc analysis by Tukeys test; Error bars represent SD; n = 3.
doi:10.1371/journal.pone.0055282.g006
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effect of dendrimers, it just optimizes it, and so an acidic
environment intracellularly cannot be automatically assumed
(unpublished data). Finally, the fact that PPI dendrimers localize
predominantly in lysosomes is not surprising as most endocytosed
materials will end up there. Hence the argument for various
dendrimers eliminating prions by increasing their lysosomal
degradation is less robust than first impressions would lead one
to believe. That said, the ability of numerous dendrimers to render
PrPSc protease sensitive in vitro does suggest that dendrimer
induced intracellular degradation of PrPSc is quite possible. The
approach employed in this study makes no presumptions on
whether or not mPPIg5 interferes with the degradation of PrPSc. It
solely examines the issue of whether or not the conversion of PrPC
to PrPSc is being inhibited. For drugs such as STI571 which do not
inhibit the conversion process but clearly eliminate prions from
infected cells, the nSCA can be used to determine that they must
work by increasing degradation through a process of elimination.
However the nSCA system cannot be used to tell whether a drug
works by both inhibiting conversion and increasing degradation of
PrPSc or by solely inhibiting the conversion of PrPC to PrPSc.
Hence it is quite possible that mPPIg5 is able to eliminate prions
from a cell by both inhibiting the conversion of PrPC to misfolded
forms and increasing the degradation of PrPSc as in vitro
experiments suggest.
Evidence for other dendrimers inhibiting the conversion of PrPC
to PrPSc is indirectly supplied from previous studies. An
investigation with permanently charged quaternized dendrimers
showed that versions of these dendrimers which demonstrated no
activity against prions in vitro, are capable of eliminating prions
intracellularly and inhibiting PrP aggregate formation in PMCA
experiments. This suggested to the authors that something other
than dendrimer induced degradation of prions may be taking
Figure 7. mPPIg5 effect on subcellular distribution of PrPC. A) Confocal microscopy was used to examine the cellular localization of PrPC.
N2a#58 cells grown on coverslips were mock treated, treated with 20 mg/ml mPPIg5 or treated with 200 mg/ml suramin for 48 hours. Cells were then
permeabilized or left intact before immuno-staining with SAF32 and Alexa488 secondary antibody for PrPC. Hoechst 33342 was used to stain DNA. All
images were acquired using equal settings. n = 2. B) Phosphatidylinositol-specific phospholipase C (PIPLC) was used to validate the confocal
microscopy result. N2a#58 cells were treated with 20 mg/ml mPPIg5 (lanes 2, 4, 6 and 8) or mock treated (lanes 1, 3, 5 and 7) for 48 hours. Cells were
washed with PBS then treated for two hours with 0.5U/ml PIPLC in serum free DMEM (lanes 3, 4, 7 and 8) or mock treated with serum free DMEM
(lanes 1, 2, 5 and 6). The media was collected, ethanol precipitated and examined for PrPC by immunoblotting with SAF83 antibody (lanes 5–8). The
remaining cells were lysed and a portion examined for PrPC by immunoblot (lanes 1–4). Apparent molecular mass based on migration of protein
standards is indicated for 17, 25, and 30 kDa. C) Biosynthesis of PrPC was examined by metabolic labelling. N2a cells were transfected with PrPC and
labelled with [35S] methionine for 1 hour. After labelling cells were either analysed directly (Pulse), or incubated in fresh medium for additional 4 h
(Chase). When indicated, mPPIg5 was present during the starving, labelling and chase periods (final concentration 20 mg/ml). PrP was
immunoprecipitated by using the monoclonal anti-PrP antibody 3F4 and analysed by SDS-PAGE and autoradiography. Apparent molecular mass
based on migration of protein standards is indicated for 16, 22, and 36 kDa.
doi:10.1371/journal.pone.0055282.g007
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place such as inhibition of PrPC to PrPSc conversion [12]. In this
study we demonstrated a similar result whereby mPPIg5 was not
effective against 22L in an in vitro setting but highly effective in an
intracellular setting (Figure 3). Additionally, experiments with the
PAMAM generation 7 (PAMAMg7) dendrimer have demonstrat-
ed that this polyamine causes a dramatic accumulation of an
insoluble, protease-sensitive PrP aggregate, believed to be
produced directly from PrPC. It is possible that this aggregate
inhibits the formation of PrPSc by sequestering PrPC [11]. Our
study did not reveal any evidence of such non-infectious PrP
aggregates following treatment with mPPIg5 suggesting this may
be an effect specific to PAMAM or perhaps even high generation
dendrimers.
mPPIg5 has no effect on PrPC synthesis and localization as
demonstrated by confocal microscopy, pulse chase and PIPLC
experiments. Since mPPIg5 has no discernible effect on PrPC, how
then does it inhibit the conversion of PrPC R PrPSc? There are a
number of possibilities. mPPIg5 may competitively inhibit the
interaction between PrPC and PrPSc. Or it may interfere with
components of PrPSc formation which have not yet been identified
such as short-lived PrPC R PrPSc intermediates or potential co-
factors like RNA which are necessary for PrPSc formation [33].
Alternatively PrPSc trafficking may be interfered with to the extent
that it is no longer available for the conversion of PrPC.
Perhaps the most likely explanation is that mPPIg5 alters the
structure of PrPSc to such an extent that it is no longer capable of
initiating the misfolding of PrPC. Evidence for dendrimers
effecting the structure of PrPSc comes from in vitro studies with
prion infected brain homogenate, demonstrating that various
dendrimers appear to denature PrPSc molecules and render them
susceptible to proteolysis [6,7]. Additionally, Fourier transform
infrared spectroscopy and electron microscopy studies have
demonstrated that purified prions treated with PPI dendrimers
lose b-sheet structure and become disaggregated [7]. Dendrimers
altering the confirmation of the PrPSc molecule can thus serve as
an explanation for both the in vitro and intracellular activity of all
dendrimers. One could envisage dendrimers interacting with the
PrPSc molecule (both in vitro and intracellularly) and altering its
structure in a process that is governed by the original confirmation
of the PrPSc molecule (influenced by the type of prion strain) and
on the chemical nature of the dendrimer (dependant on a
combination of the dendrimers size, structure, charge and density
of reactive surface groups). In some instances, the interaction will
alter the PrPSc structure to the extent that it becomes susceptible to
proteolysis, both in an in vitro and intracellular setting. In other
cases the interaction will not be sufficient to render PrPSc
susceptible to proteolysis but it will alter the PrPSc molecule to
the extent that it can no longer convert PrPC to the misfolded
form. This would explain how some dendrimers apparently fail to
reduce protease resistant PrPSc in vitro but can be effective
intracellularly. Additionally, such a scenario would allow a
dendrimer to eliminate prions intracellularly by both increasing
their degradation as the original experiments in this area suggest
[6,7,34] and/or eliminate prions by inhibiting the conversion of
PrPC to PrPSc as some of the more recent studies in this area,
including our own, suggest [11,12].
Dendrimers affecting the structure of misfolded PrP may also
explain how numerous dendrimers (including mPPI) inhibit the
fibrilization of PrP peptides in vitro [13,35–40]. This ability is
believed to be due to dendrimers increasing the fibril breakage rate
or blocking the end of growing fibrils [41,42]. Both of these
scenarios are possible in an intracellular setting. However
dendrimers blocking the end of growing fibrils cannot explain
the ability of various dendrimers to reduce PrPSc in prion infected
brain homogenate [6,7,14,34]. Dendrimers increasing the fibril
breakage rate on the other hand can explain this ability and again
may be linked back to specific dendrimers having an effect on the
structure of misfolded PrP. Hence an ability to alter the structure
of PrPSc can explain the various anti-prion activities of dendrimers
in an intracellular and in vitro setting. Whilst it is possible that
different dendrimers may achieve their anti-prion effect through a
variety of mechanisms, Occam9s razor dictates that a single
explanation is the most likely. Additional experiments are
necessary before this hypothesis could be accepted. What this
study demonstrates is that mPPIg5 inhibits the conversion of PrPC
to PrPSc. Understanding the basis of the anti-prion activity of other
dendrimers remains an exciting challenge.
This study also involved the development of the modified SCA
(mSCA) as a high throughput and fully quantitative system for
monitoring the elimination of prions in infected cells over time.
The traditional method for assessing a drug’s anti-prion effect in
an intracellular setting relies on the PK digestion and immuno-
blotting of samples followed by densitometry to quantify the result.
Such immunoblot based assays are labour intensive and the
densitometry involved generates, at best, a semi-quantitative
result. The mSCA is a marked improvement over these traditional
methods. It offers a number of advantages in speed and
throughput for the assessment of the efficacy of anti-prion drugs
and is suitable for the mass screening of compounds.
In conclusion, this study highlights how the mSCA and nSCA
represent exciting new tools for investigating the efficacy and mode
of action of novel anti-prion compounds. These assays were utilised
to demonstrate that mPPIg5 is an effective anti-prion compound
capable of inhibiting the conversion of PrPC to PrPSc. Understand-
ing how a drug works is a vital component in maximising its
performance. By establishing that mPPIg5 interferes with the
conversion of PrPC to PrPSc, this study will help determine what
other drugsmay enhance this effect. The low cytotoxicity ofmPPIg5
and the recently demonstrated ability of maltotriose dendrimers to
cross the blood to brain barrier [30] suggests that mPPIg5 is one of
the most promising anti-prion therapeutics currently available and
worthy of further investigation.
Supporting Information
Figure S1 ELISPOT after mSCA and sSCA. Elispot well
after the mSCA and the sSCA of N2a and ScN2a cells. The spots
visible on the ELISPOT membrane reflect cells containing PrPSc.
The spots produced by the mSCA are sharper and more intense
than those produced by sSCA. All images were captured in
maximum focus and not subsequently altered in any way.
(TIF)
Figure S2 Optimum mPPIg5 treatment concentration.
22LN2a#58 cells were treated with increasing concentrations of
mPPIg5 for A) 26 hours or B) 72 hours before analysis by mSCA
(20,000 cells/well). The optimum concentration of mPPIg5 for
PrPSc elimination was found to be 10–20 mg/ml, which is similar
to that calculated for the elimination of PrPSc in RML infected
cells 14). Error bars represent SD; n= 3.
(TIF)
Figure S3 Preparation and validation of PrP27–30. A) To
generate PrP27–30 free of any traces of FL PrPSc an innovative
method was employed. ScN2a cells were lysed in a minimum
detergent lysis buffer to reduce the toxicity of the extract.
Following this, PrPSc present in the lysate was reduced to PrP27–
30 using an extended PK digest and wash protocol. To ensure that
the PrP27–30 produced was N terminally cleaved an immunoblot
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was performed with monoclonal antibody SAF32 (specific for the
N terminal of PrP; lane 1 and 2) and SAF83 (specific for the
protease resistant core of PrP27–30; lane 3 and 4). Samples in lane 1
and 3 are non-protease treated controls whilst samples in lane 2
and 4 were PK treated for 2 hours. Apparent molecular mass
based on migration of protein standards is indicated for 17, 25,
and 30 kDa. B) The infectivity of the PrP27–30 produced (and
hence its similarity to endogenous PrP27–30) was examined by the
scrapie cell assay. A highly susceptible subclone of N2a cells
(N2a29) and a subclone resistant to prion infection (N2a6) created
in our laboratory were seeded onto a 96 well TC plate and
inoculated with various dilutions of PrP27–30 purified from ScN2a
cells. The cells were passaged four times to dilute the original
inoculate and then examined via mSCA for infected N2a cells. A
1/10 dilution of PrP27–30 proved toxic to the cells. N2a cells
resistant to prion infection (N2a6) were used to show that none of
the original PrP27–30 inoculate was detectable after 4 passages.
Error bars represent SD; n= 3 (technical, not biological repeats).
The immunoblotting and infectivity study demonstrated that the
PrP27–30 prepared from ScN2a cells lacked the N terminal but
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